BioDelivery Sciences International Inc
F:BD5
BioDelivery Sciences International Inc
Inventory
BioDelivery Sciences International Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
Inventory
$23.7m
|
CAGR 3-Years
64%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$11.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$12.2B
|
CAGR 3-Years
41%
|
CAGR 5-Years
25%
|
CAGR 10-Years
13%
|
|
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
See Also
What is BioDelivery Sciences International Inc's Inventory?
Inventory
23.7m
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Inventory amounts to 23.7m USD.
What is BioDelivery Sciences International Inc's Inventory growth rate?
Inventory CAGR 5Y
47%
Over the last year, the Inventory growth was 36%. The average annual Inventory growth rates for BioDelivery Sciences International Inc have been 64% over the past three years , 47% over the past five years .
